Late onset infectious complications and safety of tocilizumab in the management of COVID-19.

Natasha N PettitCynthia T NguyenGökhan M MutluDavid WuLucas KimmigDavid PitrakKenneth Pursell

Published in: Journal of medical virology (2020)

Late onset infections were significantly more common among those receiving TCZ. Combining infections and TCZ-related toxicities, 61% of patients had a possible post-TCZ complication. While awaiting clinical trial results to establish the efficacy of TCZ for COVID-19 related CRS, the potential for infections and TCZ related toxicities should be carefully weighed when considering use.

Keyphrases

late onset
early onset
coronavirus disease
clinical trial
sars cov
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
study protocol
risk factors
respiratory syndrome coronavirus
systemic lupus erythematosus
juvenile idiopathic arthritis
climate change
patient reported
double blind